Hormonal
Semaglutide 2.4 mg weekly produces significant weight loss (approx. 14.9%) in overweight and obese adults without diabetes, significantly outperforming placebo and older GLP-1 agonists like liraglutide.
Semaglutide 2.4 mg (Wegovy) is a once-weekly injection approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Clinical trials show it can lead to an average 14.9% body weight loss over 68 weeks when combined with diet and exercise. This is significantly more effective than older GLP-1 drugs like liraglutide. Common side effects include nausea and diarrhea, which are usually mild and decrease over time.
Semaglutide 2.4 mg once weekly was associated with a significant weight reduction (-14.9% in the semaglutide group compared with -2.4% in the placebo group) during 68 weeks in overweight and obese participants without diabetes [135].
Why this rating
Based on large-scale, randomized, double-blind, placebo-controlled clinical trials (STEP 1).
Source
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Eun Roh et al. · International Journal of Molecular Sciences · 2023
DOI 10.3390/ijms24043384
More from this paper
- Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce significantly greater weight loss (up to 20.9%) compared to selective GLP-1 receptor agonists (e.g., semaglutide) by activating both GIP and GLP-1 signaling pathways in the brain and peripheral tissues.Strong
- Gut hormones (GLP-1, GIP, CCK, PYY, OXM) regulate food intake and energy homeostasis by acting on the hypothalamus and brainstem via direct circulation or vagus nerve signaling, while ghrelin stimulates appetite.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →